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Abstract Keratinocyte growth factor receptor (KGFR) is a
receptor tyrosine kinase expressed on epithelial cells. Following
ligand binding, KGFR is rapidly activated and internalized by
clathrin-mediated endocytosis. Among the possible receptor sub-
strates which could be involved in the regulation of KGFR en-
docytosis and down-modulation, we analyzed here the eps15
protein in view of the proposed general role of eps15 in regulat-
ing clathrin-mediated endocytosis as well as that of eps15 tyro-
sine phosphorylation in the control of regulated endocytosis.
Immunoprecipitation and Western blot analysis showed that ac-
tivated KGFR was not able to phosphorylate eps15, suggesting
that eps15 is not a receptor substrate. Double immuno£uores-
cence and confocal microscopy revealed that activated KGFR,
di¡erently from epidermal growth factor receptor (EGFR), did
not induce recruitment of eps15 to the cell plasma membrane.
Microinjection of a monoclonal antibody directed against the
C-terminal DPF domain which contains the AP2 binding region
of eps15 led to inhibition of both pathways of receptor-mediated
endocytosis, the EGFR ligand-induced endocytosis and the
transferrin constitutive endocytosis, but did not appear to block
the KGFR ligand-induced internalization. Taken together our
results indicate that the clathrin-mediated uptake of KGFR is
not mediated by eps15.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Clathrin-mediated endocytosis represents a selective and ef-
¢cient cellular mechanism of uptake, regulated by multiple
interactions among proteins which function as adapters or
accessory components and form active complexes. Among
them, the eps15 protein was initially identi¢ed as a substrate
of the epidermal growth factor receptor (EGFR) [1], but sev-
eral further lines of evidence strongly suggested that eps15 is
involved in receptor-mediated endocytosis. The eps15 protein,
in fact, is constitutively associated with the adapter protein
AP2 [2] and contains three eps15 homology domains in the
N-terminal portion, responsible for multiple interactions with
proteins of the endocytic machinery [3^5]. Moreover, the in-
hibition of both EGFR and transferrin receptor (TfR) inter-
nalization through microinjection of anti-eps15 antibodies or
overexpression of dominant negative mutants of eps15 sug-
gested that the protein could play a general role in the control
of either constitutive or ligand-induced endocytosis [6,7]. Pre-
vious observations from our group, in addition, showed that
eps15 colocalizes with EGFR during early and late steps of
endocytosis, suggesting that the protein could have multiple
roles in di¡erent stages of the endocytic process [8]. Finally, it
has been proposed that eps15 phosphorylation is essential for
ligand-induced EGFR, but not for constitutive TfR internal-
ization [9] ; overexpression of the eps15 tyrosine mutant, how-
ever, does not a¡ect EGFR clustering, eps15 recruitment to
the plasma membrane and clathrin-coating formation suggest-
ing that tyrosine phosphorylation of eps15 could be a molec-
ular modi¢cation required for events following clathrin-coated
pit formation, such as vesiculation.
We have recently analyzed the endocytic pathway of the
keratinocyte growth factor receptor (KGFR), a receptor tyro-
sine kinase (RTK) which is a splicing variant of the ¢broblast
growth factor receptor 2 (FGFR2) [10,11] ; we showed that,
di¡erently from other members of the FGFR family [12^14],
KGFR enters the cell following ligand binding through clath-
rin-coated pits and that this clathrin-mediated endocytosis
leads to rapid internalization of the activated receptors [15,16].
In an attempt to investigate the possible role of eps15 in
regulating KGFR uptake at the plasma membrane, we found
that eps15, di¡erently from EGFR but similarly to other
RTKs such as platelet-derived growth factor receptor and
insulin receptor [17], is not tyrosine-phosphorylated by
KGFR when activated by its ligand. We decided therefore
to compare the pattern of distribution in unstimulated cells
and redistribution upon activation of EGFR and KGFR. Our
results showed that: (1) eps15 is neither phosphorylated nor
recruited to the plasma membrane after KGF-induced KGFR
activation and (2) microinjection of an anti-eps15 monoclonal
antibody (mAb) blocks EGFR and TfR but not KGFR in-
ternalization suggesting that clathrin-dependent ligand-medi-
ated endocytosis, at least in the case of KGFR, can occur
without the direct or indirect involvement of eps15.
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2. Materials and methods
2.1. Cell lines
NIH3T3 cells, NIH3T3 EGFR [18] and NIH3T3 KGFR [19] trans-
fected cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM), supplemented with 10% fetal calf serum or calf serum
plus antibiotics, plated at a density of 8U104 cells on round glass
coverslips coated with 2% gelatin (Sigma, St. Louis, MO, USA).
The human keratinocyte cell line HaCaT was cultured in DMEM
supplemented with 10% fetal bovine serum and antibiotics.
For treatment with KGF or with KGF-HFc chimeric protein, ob-
tained by fusion of KGF with the HFc portion of immunoglobulin G
[19], cells were serum-starved for 12 h, washed with cold medium,
incubated with 100 ng/ml KGF (Upstate Biotechnology, Lake Placid,
NY, USA) or with KGF-HFc in DMEM containing 0.3 M NaCl for
1 h at 4‡C and immediately ¢xed or washed with prewarmed medium
in the absence of 0.3 M NaCl and incubated at 37‡C for an additional
30 min. For EGF treatment, cells were washed with cold medium and
incubated with 100 ng/ml EGF (Upstate) or with 2 Wg/ml rhodamine-
conjugated EGF (Molecular Probes, Eugene, OR, USA) in DMEM at
4‡C for 1 h and then warmed to 37‡C for an additional 30 min. To
induce Tf internalization, cells were incubated with 50 Wg/ml Tf-Texas
red (Molecular Probes) in DMEM for 10 min at 37‡C before ¢xation.
2.2. Microinjection
Microinjection was performed using an Eppendorf microinjector
(Eppendorf, Hamburg, Germany) and an inverted microscope (Zeiss,
Oberkochen, Germany). Injection pressure was set at 30^80 hPa and
the injection time at 0.3^0.5 s. Anti-eps15 mAb VV1 and control
mouse IgG were microinjected into the cytoplasm of the cells at a
concentration of 1 mg/ml. At 30 min after injection, cells were incu-
bated with KGF, EGF or Tf as above to induce clathrin-mediated
endocytosis.
2.3. Generation and puri¢cation of anti-eps15 mAb VV1
An anti-eps15 mouse mAb denominated VV1 was generated using
recombinant eps15 glutathione S-transferase (GST) fusion protein ([1]
and kindly provided by Prof. Di Fiore, Milan, Italy) as antigen source
to immunize BALB/c mice. Hybridomas were obtained by fusion of
NS-1 myeloma cells with spleen cells from immunized mice. The spec-
i¢city of hybridomas was analyzed in enzyme-linked immunosorbent
assay (ELISA) using pGEX-eps15 and pGEX as negative control
(kindly provided by Prof. Di Fiore, Milan, Italy). mAb VV1 (isotype
IgG1) was selected on the basis of speci¢c reactivity with the eps15
protein in ELISA. The anti-eps15 mAb VV1 was then further selected
in ELISA using a C-terminal eps15 fragment containing the DPF
domain and then puri¢ed as described [20].
2.4. Immunoprecipitation and Western blot analysis
For the further characterization of the VV1 anti-eps15 mAb, sub-
con£uent cultures of NIH3T3 ¢broblasts and con£uent cultures of
human HaCaT keratinocytes were lysed and subjected to electropho-
resis on 7% sodium dodecyl sulfate^polyacrylamide gel electrophoresis
as previously described [16]. The blots were then incubated for 1 h at
room temperature with the anti-eps15 mAb VV1 (at 20 Wg/ml) or with
the anti-eps15 polyclonal antibodies (pAb) (Santa Cruz) (1/500), fol-
lowed by enhanced chemiluminescence detection (Amersham, Arling-
ton Heights, IL, USA). For immunoprecipitation, 250 Wg of cell ly-
sates was precipitated using 3 Wg/ml of mAb VV1, 4 Wg of anti-eps15
pAbs (Santa Cruz) or an unrelated murine mAb for 2 h at 4‡C, and
immune complexes were recovered by absorption to protein A-Se-
pharose (Amersham). Immunoprecipitated proteins were then pro-
cessed for immunoblotting with the anti-eps15 full-length pAbs as
above. A polyclonal rabbit antiserum directed against the full-length
eps15 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as
positive control and puri¢ed mouse immunoglobulins detecting unre-
lated antigens and rabbit non-immune serum were used as negative
controls.
For the detection of eps15 tyrosine phosphorylation, NIH3T3
KGFR and NIH3T3 EGFR cells, serum-starved for 12 h, were left
untreated or treated with 100 ng/ml KGF, 0.3 M NaCl and 100 ng/ml
EGF (Upstate Biotechnology) for 10 min at 37‡C or for 1 h at 4‡C.
Following incubation, the cells were lysed as described [16] and 3 mg
of total protein was immunoprecipitated with 4 Wg of an anti-eps15
pAb (Santa Cruz). The membrane was probed for 1 h with an anti-
phosphotyrosine mAb (Upstate Biotechnology) at 1:1000 dilution and
then was stripped and reprobed with the anti-eps15 pAbs diluted
1:500.
For the detection of KGFR tyrosine phosphorylation, NIH3T3
KGFR cells, serum-starved for 12 h, were left untreated or treated
with KGF as above. 1 mg of total protein was immunoprecipitated
with 4 Wg of anti-Bek pAbs (C-17; Santa Cruz) as previously de-
scribed [16]. The membrane was probed for 1 h with anti-phosphoty-
rosine as above. The ¢lter was stripped and reprobed with the anti-
Bek pAbs, diluted 1:500.
For the detection of EGFR tyrosine phosphorylation, NIH3T3
EGFR cells, serum-starved for 12 h, were left untreated or treated
with EGF as above. 1 mg of total protein was immunoprecipitated
with 4 Wg of an anti-EGFR mAb (528; Santa Cruz) and the mem-
brane was probed for 1 h with anti-phosphotyrosine as above. The
¢lter was stripped and reprobed with anti-EGFR pAb, diluted 1:500
(1005; Santa Cruz).
2.5. Immuno£uorescence
For conventional immuno£uorescence, cells grown on coverslips
were ¢xed in methanol at 320‡C for 4 min and, after washing in
phosphate-bu¡ered saline (PBS), incubated for 1 h at 25‡C with
anti-eps15 mAb VV1 (1:100 in PBS). The bound antibodies were vi-
Fig. 1. Tyrosine phosphorylation of eps15 following EGFR but not
KGFR activation. NIH3T3 KGFR and NIH3T3 EGFR cells were
serum-starved for 12 h and then left untreated or treated with KGF
or EGF for 1 h at 4‡C. Cell lysates were immunoprecipitated with
anti-eps15 antibodies and then immunoblotted with anti-phosphoty-
rosine (PY) antibody or with anti-eps15 antibodies (A). Alternatively,
cell lysates were immunoprecipitated with anti-Bek antibody (B, left)
or with anti-EGFR antibody (B, right) and then immunoblotted
with anti-PY antibody or with anti-Bek (B, left) or anti-EGFR
(B, right) antibodies. Eps15 protein appears tyrosine-phosphorylated
in response to EGF treatment, but not in response to KGF, where-
as both KGFR and EGFR were tyrosine-phosphorylated in re-
sponse to the growth factors.
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Fig. 2. a: Confocal analysis of the localization of eps15 after KGFR or EGFR activation. NIH3T3 KGFR cells untreated or treated with
KGF for 1 h at 4‡C were ¢xed and doubly immunolabeled with anti-eps15 pAbs (green) and anti-Bek mAb (red). Confocal analysis shows
that, in untreated NIH3T3 KGFR cells, the eps15 punctate staining does not colocalize with KGFR signal at the cell surface (A) and that the
eps15 distribution is not modi¢ed by the KGF treatment (B). NIH3T3 EGFR untreated or treated with EGF for 1 h at 4‡C was doubly immu-
nolabeled with anti-eps15 pAbs (green) and anti-EGFR mAb (red). In untreated NIH3T3 EGFR, the eps15 staining appears distributed in the
cytosol and does not colocalize with the EGFR on the cell plasma membrane (C); after treatment with EGF, the eps15 signal appears partially
redistributed and localized under the plasma membrane where colocalization of the protein with EGFR is observed (D, arrows). Eps15 recruit-
ment to the plasma membrane is not evident in cells that express low levels of EGFR (asterisk). The extent of colocalization is shown in yellow
after merging or as white dots after masking the images. Bars: 10 Wm. b: NIH3T3 KGFR and NIH3T3 EGFR cells treated with KGF-HFc or
EGF-TRITC for 1 h at 4‡C were doubly immunolabeled with anti-ep15 antibodies. Confocal analysis reveals that eps15 is not recruited to the
plasma membrane after KGF-HFc binding and does not colocalize with the KGF-HFc signal distributed on the surface of NIH3T3 KGFR
cells (A). In contrast, treatment with EGF-TRITC induces redistribution of eps15 toward the plasma membrane, where the staining correspond-
ing to eps15 colocalizes with the EGF-TRITC signal (B, arrows). Eps15 redistribution to the plasma membrane is not evident in cells that ex-
press low levels of EGFR (asterisk). The extent of colocalization is shown in yellow after merging or as white dots after masking the images.
Bars: 10 Wm.
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sualized with FITC-conjugated goat anti-mouse IgG (1:50 in PBS)
(Cappel Research Products, Durham, NC, USA). In double immuno-
£uorescence experiments after treatment with KGF, KGF-HFc or
EGF as above, cells were ¢xed in methanol at 320‡C for 4 min
and then incubated with the following primary antibodies: anti-
eps15 mAb VV1 (1:100 in PBS), anti-eps15 pAbs (1:100 in PBS)
(kindly provided by Prof. P.P. Di Fiore, Milan, Italy), anti-Bek
pAbs (1:10 in PBS), anti-Bek mAb (1:10 in PBS) (C8, Santa Cruz)
or with anti-EGFR mAb (1:50 in PBS) (528, Santa Cruz). The pri-
mary antibodies were visualized using: FITC-conjugated goat anti-
mouse IgG as above, FITC-conjugated goat anti-rabbit IgG (1:300
in PBS) (Cappel), Texas red-conjugated goat anti-mouse IgG (1:50 in
PBS) (Jackson Immunoresearch Laboratories, West Grove, PA, USA)
or Texas red-conjugated goat anti-rabbit IgG (1:100 in PBS) (Jack-
son). KGF-HFc was visualized using FITC-conjugated goat anti-
mouse IgG as above. Colocalization of £uorescence signals was eval-
uated using a Zeiss confocal laser scan microscope. To prevent cross-
talk between the two signals, the multitrack function was used.
After microinjection, cells were ¢xed with 4% paraformaldehyde in
PBS (30 min at 25‡C) and permeabilized with 0.1% Triton X-100 in
PBS for 5 min. To identify injected cells, they were incubated with
FITC-conjugated goat anti-mouse IgG as above. Coverslips were ¢-
nally mounted with 90% glycerol in PBS for observation with a Zeiss
Axiophot epi£uorescence microscope. Fluorescence signals were ana-
lyzed either by recording stained images using a cooled CCD color
digital camera SPOT-2 (Diagnostic Instruments, Sterling Heights, MI,
USA) and FISH 2000/H1 software (Delta Sistemi, Rome, Italy).
Quantitative analysis of the receptor internalization in injected cells
was performed evaluating ¢ve di¡erent areas of each slide randomly
taken from three di¡erent experiments: results are expressed as per-
centage of injected cells showing KGFR or EGFR £uorescence signal
at the cell plasma membrane.
3. Results
3.1. Eps15 is not tyrosine-phosphorylated by KGF-induced
receptor activation
To ¢rst determine whether eps15 would undergo tyrosine
phosphorylation upon KGFR activation at the cell plasma
membrane as induced by ligand binding at 4‡C, NIH3T3
KGFR cells were serum-starved for 12 h, left untreated or
treated with KGF (100 ng/ml) for 1 h at 4‡C, then immuno-
precipitated with anti-eps15 pAbs and immunoblotted with
anti-phosphotyrosine mAb. To compare the possible e¡ect
induced by KGFR activation on eps15 phosphorylation
with the known e¡ect induced by EGFR activation at 4‡C
[8], NIH3T3 EGFR cells were serum-starved for 12 h, left
untreated or treated with EGF (100 ng/ml) for 1 h at 4‡C,
and immunoprecipitated with anti-eps15 mAb and then blot-
ted with anti-phosphotyrosine antibody as above. KGF treat-
ment of NIH3T3 KGFR cells resulted in no tyrosine phos-
phorylation of the eps15 protein (Fig. 1A), although the same
treatment was able to induce tyrosine phosphorylation of
KGFR as expected [17], assessed by immunoprecipitation
with anti-Bek antibodies and Western blot with anti-phospho-
tyrosine antibodies (Fig. 1B, left panel). In contrast, treatment
of NIH3T3 EGFR cells with EGF appeared to trigger tyro-
sine phosphorylation of both eps15 (Fig. 1A) and EGFR (Fig.
1B, right panel), as previously reported [8]. In order to eval-
uate if the phosphorylation of eps15 by KGFR could require
the recruitment of the receptor into clathrin-coated pits, which
is known to be inhibited at 4‡C, eps15 phosphorylation was
also analyzed after treatment of NIH3T3 KGFR transfectants
with KGF for 10 min at 37‡C, in comparison with parallel
treatment of NIH3T3 EGFR cells with EGF for 10 min at
37‡C. However, also in these conditions, eps15 was tyrosine-
phosphorylated by EGF, but not by KGF incubation (data
not shown).
Thus eps15 does not appear to be tyrosine-phosphorylated
by KGF-induced KGFR activation, indicating that eps15 is
not a substrate of the KGFR kinase.
3.2. KGFR activation does not induce recruitment of eps15 to
the plasma membrane
To evaluate if eps15 would be recruited to the cell plasma
Fig. 2 (Continued).
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membranes following KGFR tyrosine phosphorylation and
activation, as previously demonstrated for EGFR [8], we an-
alyzed by immuno£uorescence and confocal microscopy the
localization of eps15 after KGFR and EGFR activation.
NIH3T3 KGFR and NIH3T3 EGFR cells treated or not
with KGF and EGF for 1 h at 4‡C were ¢xed and processed
for double immuno£uorescence with anti-eps15 pAbs and
with anti-Bek mAb or anti-EGFR mAb, respectively (Fig.
2a). In untreated cells, eps15 staining appeared in intracellular
dots present at the cell periphery as well as in the central areas
of the cell cytoplasm, as expected [8] (Fig. 2a, A and C),
whereas both KGFR and EGFR signals were distributed
mainly on the cell plasma membrane, although intracellular
perinuclear staining corresponding to synthesizing receptors
was also evident (Fig. 2a, A and C). Confocal analysis showed
that the eps15 punctate signal did not colocalize with KGFR
(Fig. 2a, A) or EGFR (Fig. 2a, C).
Treatment of NIH3T3 KGFR cells with KGF for 1 h at
4‡C did not induce eps15 relocation; in fact, staining for
eps15 appeared distributed in dots scattered throughout the
entire cytoplasm and did not colocalize with KGFRs present
on the cell plasma membrane of the transfected cells (Fig. 2a,
B). In contrast, EGF treatment of NIH3T3 EGFR cells at
4‡C induced recruitment of eps15 to the plasma membrane
(Fig. 2a, D arrows) as demonstrated by colocalization of the
signal corresponding to eps15 with EGFRs present on the cell
surface (Fig. 2a, D arrows), as expected [8]. Moreover, eps15
recruitment could not be observed in cells expressing only
undetectable levels of EGFR among the transfected ones
(Fig. 2a, D asterisk).
To con¢rm our observations and to unequivocally display
the recruitment of eps15 at the plasma membrane after EGFR
but not after KGFR activation, without the possible interfer-
ence of intracellular receptors, we used directly or indirectly
£uorochrome-conjugated ligands bound at the cell plasma
membranes to visualize the activated receptors. NIH3T3
KGFR cells, starved for 12 h, were treated for 1 h at 4‡C
with a functional KGF-HFc chimeric protein obtained by
fusion of KGF with the HFc fragment of IgG which possesses
binding and activating properties of the KGF ligand
[16,19,21], followed by ¢xation and incubation with a second-
ary anti-IgG antibody. In parallel experiments, NIH3T3
EGFR cells were incubated with EGF-TRITC for 1 h at
4‡C and immediately ¢xed. Cells were then processed for
double immuno£uorescence using anti-eps15 pAbs as above.
Confocal analysis showed that eps15 did not colocalize with
cell surface KGFRs stained with KGF-HFc (Fig. 2b, A),
whereas evident colocalization of EGFRs stained with EGF-
TRITC and eps15 was observed (Fig. 2b, B).
Thus KGFR activation, di¡erently from EGFR activation,
does not induce either eps15 phosphorylation or protein re-
cruitment to the plasma membrane.
3.3. KGFR endocytosis is not blocked by microinjection of
anti-eps15 mAb
To directly analyze the possible role of eps15 in regulating
the KGFR endocytic process compared to EGFR and to
better de¢ne the function of the C-terminal DPF domain
(containing the AP2 binding L2 region) in this process, we
utilized an anti-eps15 murine mAb which has been generated
and characterized. First mAb screening was performed by
ELISA using the GST eps15 recombinant protein and the
related fragments: one murine mAb speci¢cally recognizing
the C-terminal DPF domain was selected and named VV1
(data not shown). Fig. 3a illustrates that VV1 mAb is able
to detect the eps15 protein either by direct immunoblotting
performed on NIH3T3 cell lysates as well as on the GST
recombinant protein or by immunoprecipitation of NIH3T3
cell lysates. In fact, Western blot analysis showed that the
anti-eps15 mAb VV1 speci¢cally recognizes a protein species
corresponding to the molecular mass of the eps15 product
(142 kDa) in NIH3T3 cell lysates and the eps15 recombinant
protein (Fig. 3a). VV1 mAb was also able to e⁄ciently im-
munoprecipitate the eps15 protein from the NIH3T3 cell ly-
sates (Fig. 3a). An unrelated mouse puri¢ed mAb (anti-CEA)
was used as negative control. To verify eps15 expression in
normal epithelial cells which are known to express endoge-
nous KGFR, we performed parallel Western blot experiments
using the human keratinocyte HaCaT cell line grown to con-
£uence [22] ; again the anti-eps15 mAb VV1 speci¢cally rec-
ognizes a protein species corresponding to the molecular
weight of eps15 in both HaCaT and NIH3T3 cell lysates. In
immuno£uorescence experiments on both NIH3T3 and Ha-
CaT cells, the anti-eps15 VV1 mAb displayed the typical pat-
tern of staining of the protein characterized by small dots
scattered throughout the cell cytoplasm (Fig. 3a), as previ-
ously described [8]. Double immuno£uorescence and confocal
analysis performed in NIH3T3 KGFR transfected cells using
the anti-eps15 mAb and an anti-Bek pAb con¢rmed that
eps15 was not recruited to the plasma membrane following
treatment with KGF for 1 h at 4‡C: the signal corresponding
to eps15 did not appear to change its intracellular distribution
and to colocalize with KGFRs present at the cell surface (Fig.
3b), as demonstrated above using anti-eps15 pAbs.
To investigate if the anti-eps15 antibody could also block
the KGFR endocytic process, we evaluated the e¡ect of mAb
VV1 microinjection on NIH3T3 KGFR cells as well as on
HaCaT keratinocytes treated, after microinjection, with
KGF for 1 h at 4‡C followed by warming to 37‡C for 30
min to induce KGFR endocytosis. Injected cells were visual-
6
Fig. 3. a: Characterization of anti-eps15 mAb VV1. Speci¢c detection of eps15 protein by direct immunoblotting performed on NIH3T3 cell ly-
sates or on GST recombinant eps15 using the mAb VV1, anti-eps15 pAbs or an unrelated mAb (A and B). Immunoprecipitation of NIH3T3
cell lysates with mAb VV1 or anti-eps15 pAbs or an unrelated mAb followed by immunoblot analysis with anti-eps15 pAbs (C). Parallel direct
immunoblotting of cell lysates from HaCaT keratinocytes and NIH3T3 ¢broblasts with mAb VV1 (D). Immuno£uorescence analysis on
NIH3T3 cells and on HaCaT keratinocytes performed with anti-eps15 mAb VV1 displays the typical punctate staining of eps15 (E). b: Immu-
no£uorescence and confocal analysis of the localization of eps15 and KGFR after KGF treatment using the anti-eps15 mAb VV1. NIH3T3
KGFR cells untreated (A) or treated with KGF for 1 h at 4‡C (B) were doubly immunolabeled with anti-eps15 mAb VV1 and anti-KGFR
pAbs. Confocal analysis shows that eps15 is localized in intracellular dots scattered throughout the cytoplasm and does not colocalize with
KGFRs in either untreated (A) or KGF-treated cells (B); eps15 distribution is unmodi¢ed. The extent of colocalization is shown in yellow after
merging or as white dots after masking the images. Bar: 10 Wm.
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ized using FITC-conjugated goat anti-mouse IgG. Double im-
muno£uorescence with anti-Bek antibodies showed that, in
both microinjected and non-injected cells, the KGFR signal
is concentrated in intracellular endocytic structures (Fig.
4A,B). In parallel experiments, NIH3T3 EGFR cells were
microinjected with anti-eps15 mAb VV1, treated with EGF-
TRITC at 4‡C and then warmed for 30 min to 37‡C to induce
ligand-dependent internalization: the EGF-TRITC signal ap-
peared localized on the cell surfaces of the injected cells,
whereas the EGF staining was distributed intracellularly in
the uninjected ones (Fig. 4C). Alternatively, NIH3T3
KGFR were microinjected either with anti-eps15 mAb VV1
or with control mouse IgG and incubated with Tf-Texas red
for 10 min to 37‡C to follow the constitutive internalization of
Fig. 4. E¡ect of microinjected anti-eps15 mAb on KGFR, EGFR and Tf endocytosis. NIH3T3 KGFR cells (A,D,E), HaCaT keratinocytes (B)
and NIH3T3 EGFR cells (C) were microinjected with anti-eps15 mAb (A^D) or control mouse IgG (E). After microinjection, cells were incu-
bated with KGF (A,B) or EGF-TRITC (C) for 1 h at 4‡C and then warmed for 30 min to 37‡C to allow KGFR or EGFR internalization. Al-
ternatively, microinjected NIH3T3 KGFR was treated with Tf-Texas red for 10 min at 37‡C in order to permit Tf endocytosis (D,E). At the
end of the incubations at 37‡C, all microinjected cells were ¢xed and identi¢ed using FITC-conjugated goat anti-mouse IgG. Double immuno-
£uorescence with anti-Bek pAbs shows that the KGFR signal is localized in intracellular perinuclear dots either in cells microinjected with the
anti-eps15 mAb (A and B, arrows) or in uninjected cells (A and B, arrowheads). In contrast, EGF-TRITC staining remains distributed on the
cell surface in cells microinjected with anti-eps15 mAb (C, arrow), whereas it appears localized in intracellular endocytic dots in uninjected cells
(C, arrowhead). Similarly, Tf-Texas red endocytosis appears blocked in cells microinjected with the anti-eps15 mAb (D, arrow), but not in un-
injected cells among the injected ones (D, arrowheads) or in cells microinjected with the control mouse IgG (E, arrow). Quantitative analysis of
KGFR and EGFR internalization in NIH3T3 transfected cells expressed as percentage of injected cells with receptor £uorescence signal at the
cell plasma membrane. Results represent the mean values US.D. from three di¡erent experiments. Bar: 10 Wm.
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transferrin. As shown in Fig. 4D, microinjection of the mAb
VV1 drastically blocked the Tf-Texas red internalization,
whereas Tf endocytosis appeared unaltered in cells microin-
jected with control mouse IgG (Fig. 4E). Thus, injection of
the anti-eps15 mAb is able to interfere with either EGFR or
Tf endocytosis but not with KGFR endocytosis.
4. Discussion
Both the endocytic pathways followed by the RTKs of the
FGFR family and the mechanisms involved in the regulation
of these pathways have been very little investigated and only a
few reports have addressed this topic. In addition, some lines
of evidence have been presented which indicate that di¡erent
FGFRs appear to use distinct routes for their internalization
[13^15]; among them, only KGFR seems to enter the cells by
ligand-induced clathrin-mediated endocytosis [15,16]. In fact,
immunoelectron microscopic analysis of KGFR endocytosis
has previously revealed that clathrin-coated pits are involved
in the ligand^receptor uptake at the plasma membrane [15] ; in
addition, the selective block of the clathrin-mediated pathway
induced by using hypertonic medium and acidi¢cation of the
cytosol, but not the block of the caveolae-mediated pathway
obtained with ¢lipin treatment, appears to be able to inhibit
KGFR internalization (Belleudi et al., manuscript in prepara-
tion). Because of the similarity of the pathway of KGFR
internalization to that followed by EGFR [23], we decided
here to investigate the possible role of eps15 in regulating
this process. It has been reported that eps15 is recruited to
the plasma membrane after EGF-induced EGFR phosphory-
lation [8] and that microinjection of anti-eps15 antibodies or
overexpression of dominant negative domains of the protein
blocks EGFR and Tf internalization [6], demonstrating that
eps15 plays a general role in both ligand-dependent and con-
stitutive clathrin-mediated endocytosis. It has also been pro-
posed that eps15 tyrosine phosphorylation is not required for
the function of the protein in regulating constitutive endocy-
tosis, but it is necessary for the ligand-dependent receptor
internalization [9]. Our results, however, demonstrate that:
(a) eps15 is not tyrosine-phosphorylated in response to
KGF stimulation, despite e⁄cient phosphorylation of the
KGFR, and (b) the injection of an anti-eps15 mAb interferes,
as expected [6], with the EGFR internalization, but it does not
inhibit KGFR internalization, suggesting that the clathrin-
mediated process involved in the uptake of KGF^KGFR
complexes is not mediated by eps15.
Numerous multivalent proteins and multiple alternative and
redundant mechanisms are thought to function in RTK clath-
rin-mediated endocytosis (for recent reviews see [24,25]).
EGFR endocytosis, for example, occurs through clathrin-
coated pits even independently of AP2 binding to the acti-
vated receptors [26] and adapters and/or signaling substrate
proteins other than eps15, such as Grb2 [27], epsin [5] and
c-Cbl [28], are possibly responsible for recruitment of AP2
and clathrin to the plasma membrane which triggers coated
pit assembly [29,30]. Other substrates could be possibly in-
volved in the regulation of KGFR endocytosis : it has been
shown that phospholipase CQ binds to an autophosphoryla-
tion site on FGFR1, a receptor highly related to KGFR, and
that the mutation of this tyrosine residue on the receptor
causes a block of endocytosis [31]. Moreover, it has been
shown that the other major substrate of FGFR, the FRS2K
protein, promotes the ubiquitination of FGFR1 by recruit-
ment of Cbl and controls, at least in part, the down-regulation
of the receptor [32]. Therefore, it is not surprising that eps15
does not appear to be involved either directly or indirectly in
KGFR internalization, although further work is needed to
elucidate the molecular mechanisms of this process of receptor
uptake. However, our results indicate that not only eps15
phosphorylation but also its recruitment to the plasma mem-
brane and presumably its targeting to clathrin-coated pits are
not always required for ligand-induced endocytosis and that
KGFR may represent a model system for the study of alter-
native pathways of clathrin-dependent regulated endocytosis
which may occur independently of eps15 and possibly of
eps15-interacting proteins.
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